CD274 and melanoma: Immunotherapy against PD-1 and CTLA-4 targets two mechanisms that allow melanoma to evade immune attack—PD-L1 expression on melanoma cells to inactivate cytotoxic T-cells and CTLA-4 expression on lymphocytes which inhibits T-cell activation.